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Abstract 
Purpose: To determine the expression of corticotropin-releasing hormone (CRH) in psoriasis and 
normal skin biopsy samples, and to correlate the expression of CRH with the expression of CRHBP and 
inflammatory cytokines IL-8 and IL-33. 
Methods: Psoriasis and normal skin biopsy samples were obtained from three psoriatic and three 
normal healthy patients. The mRNA expression was examined by quantitative real-time polymerase 
chain reaction (qRT-PCR). Protein expression analysis was carried out by western blotting and then 
further validated by immunohistochemistry. 
Results: The results revealed that the expression of CRH was highly significantly (p < 0.0001) in 
psoriatic skin samples compared to normal skin samples. The increase of CRH in psoriatic samples 
ranged from 2.7- to 3.5-fold. Expression of CRH was associated with concomitant downregulation of 
CRHBP in all the psoriatic skin biopsy samples. Expression of CRHBP was 3- to 6.2-fold lower in 
psoriatic samples compared to normal skin samples. Analysis of mRNA expression of IL-8 and IL-33, 
revealed that expression of both IL-8 and IL-33 was significantly (p < 0.0001) upregulated in psoriatic 
skin samples. Expression of IL-8 and IL-33 was approximately 4.1 and 3.2-fold higher in psoriatic skin 
samples than in normal skin samples. Expression of CRHBP, IL-8 and IL-33 was further confirmed by 
western blotting and immunohistochemistry which the findings from quantitative RT-PCR. 
Conclusion: Taken together, the results confirm that the expression of CRH is associated with 
suppression of CRHBP and upregulation of IL-8 and IL-33. 
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 Psoriasis is one of the chronic inflammatory skin 
disorders that affect around 3 % of the human 
population around the globe. However, studies 
have reported that the incidence of psoriasis may 
vary with race and geographical locality and the 
environmental conditions [1,2]. Psoriasis has 
broad clinical spectra ranging from the 
involvement of skin to erythroderma [3]. Psoriasis 
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has been categorized into two different types. 
Type I psoriasis is genetic, usually arises at or 
around the age of 16 years in females and 22 
years in males. Type II psoriasis is sporadic and 
generally affects the people around 60 years of 
age [4]. The development of psoriatic plaques 
triggers pain and generates a lot of discomfort 
[5].  
 
Psoriasis is accompanied by prolonged 
inflammation and it frequently co-occurs with 
inflammatory arthritis [6]. IL-33 is one of the 
newly discovered members of inflammatory 
cytokines [6] and has been reported to trigger 
IgE-triggered release of IL-8 [7]. It is well 
established in literature that stress signals such 
as psoriasis prompts the release of CRH from 
the hypothalamus paraventricular nucleus (PVN). 
CRH in turn triggers ACTH release from anterior 
pituitary [8] which ultimately controls the 
glucocorticoid discharge from adrenal cortex. 
Several of the glucocorticoids, which include but 
are not limited to cortisol, at low doses trigger 
cutaneous immune and suppress the immune 
responses at high doses [9]. In the sympathetic 
nervous system, stress stimuli cause activation 
of the locus coeruleus (LC) of norepinephrine 
cells (NE) [10]. The neuropeptides which are 
products of the sympathetic response substance 
P (SP), cutaneous nerve growth factor (NGF) 
and calcitonin gene-related peptide (CGRP), are 
reported to be pro- and anti-inflammatory 
depending on the type of the immune [11-13]. 
Moreover, it has been reported that CRH is 
tightly bound to a high affinity plasma binding 
protein (CRHBP) and CRHBP limits the 
distribution of CRH in the body [14]. In the 
current study, we examined the expression of 
CRH in psoriasis biopsy samples and correlated 
its expression with IL-8, IL-33 and CRHBP. The 
results revealed that expression of CRH is 
positively associated with expression of 
interleukin IL-8, IL-33 and negatively correlated 




Collection of samples 
 
Biopsies were taken from normal skin tissues of 
healthy volunteers as well as untreated psoriasis 
patients. The proper consent was given by the 
patients under protocols approved by the 
Institutional Review Board of Wuhan No. 1 
Hospital (No: 2016/IEC/S027). For 
immunohistochemistry analysis the samples 
were treated with formalin and paraffin 
embedded. The tissue samples were used for 
isolation of RNA, quantification protein 
expression levels of CRH, CRHBP, IL-8 and IL-
33 as described previously [15,16]. The study 
was carried out after the ethical approval was 
provided by the ethical committee of Wuhan No.1 
Hospital. The whole procedure was carried out 
by following the international guidelines as 
described previously [17]. 
 
RNA isolation, synthesis of cDNA and 
expression analysis 
 
Total RNA was isolated by RNeasy RNA 
isolation kit (Qiagen, China Shanghai Co Ltd) as 
per the manufacturer’s protocol. Thereafter, 
cDNA was synthesized with the help of 
RevertAid cDNA synthesis kit (Fermentas) as per 
the guidelines provided by the manufacturer. To 
carry out the quantification of the mRNA levels, 
the cDNA was first diluted at least 20 times and 
qRT-PCR was carried out thrice in ABI StepOne 
Real time (Applied biosystems), California, 
United States) using SYBR Green Master Mix 
(Fermentas, Massachusetts, United States). The 
relative quantification method (ΔΔ-CT) was 
employed to determine quantitative variation 
between the samples examined. β-actin was 




The skin tissues were lysed in lysis buffer and 
protein extracts were collected. Equal protein 
extracts from each group were run on SDS 
PAGE and then transferred to a polyvinylidene 
fluoride membrane. This was followed by 
blocking with 5 % non-fat milk and incubation at 
25 οC for 1h. Thereafter the membranes were 
administrated with a specific primary antibody at 
4 °C overnight. This was followed by washing in 
washing buffer and incubation for 1h with 
appropriate secondary antibody. The protein 
bands of interest were visualized with an ECL 




For immunohistochemistry, monoclonal mouse 
anti–human antibodies to IL-33 and IL-8 were 
obtained from Invitrogen, Carlsbad, CA. The 
binding of the mouse antibody was demonstrated 
in skin biopsies with the help of biotinylated 
horse anti–mouse IgG and an avidin–biotin 
complex used with a peroxidase visualization 





The data is presented as mean of three 
replicates ± SD. GraphPad Prism 7 software was 
employed to carry out one way ANOVA followed 
Su et al 
2825 
 
by Tukey’s post hoc test. The values were 
considered significant variously at *p < 0.01, **p 




Expression of CRH is highly induced in 
psoriasis 
 
It is well reported that expression of CRH is 
induced under stress conditions, therefore we 
evaluated the expression of CRH in healthy and 
psoriatic skin biopsy samples. The results 
revealed that expression of CRH was highly 
upregulated in all the psoriatic biopsy samples as 
compared to normal skin samples. The increase 
in the expression of CRH in psoriatic skin 
samples ranged from 2.7- to 3.5-fold (Figure 1). 
 
Expression of CRH is associated with 
downregulation of CRHBP 
 
Studies have reported that CRH is tightly bound 
to CRHBP that limits its distribution [18]. 
Therefore, we evaluated the expression of 
CRHBP in psoriatic and normal skin biopsy 
samples by quantitative RT-PCR. The results of 
the present investigation revealed that the 
expression of CRHBP was significantly inhibited 
in the psoriatic samples in comparison to the 
normal skin samples. 
 
 
Figure 1: Expression of CRH in normal and psoriasis skin biopsy samples determined by semiquatitative RT-
PCR analysis. Experiments were carried out in three biological replicates and presented as mean ± SD. The 
values were considered significant at *p < 0.01, **p < 0.001 and ***p < 0.0001 
 
 
Figure 2: Expression of CRHBP in normal and psoriasis skin biopsy samples determined by semi-quantitative 
RT-PCR analysis. Experiments were carried out in three biological replicates and presented as mean ± SD. The 
values were considered significant at *p < 0.01, **p < 0.001 and ***p < 0.0001 
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Expression of CRHBP was 3- to 6.2-fold lower in 
the psoriatic samples as compared to the normal 
skin samples (Figure 2). To further, confirm this 
we evaluated the expression of CRHBP in one 
normal and one psoriatic skin biopsy samples by 
western blotting. The results of western blotting 
showed similar trend as that of RT-PCR analysis 
(Figure 3). 
 
Expression of CRH is associated with 
upregulation of IL-8 and IL-33 
 
Psoriasis is one of the chronic inflammatory skin 
disorders and is always associated with 
prolonged inflammation [19]. In the current study, 
we examined the expression of inflammatory 
cytokines IL-8 and IL-33. The results showed that 
the expression of both IL-8 and IL-33 were 
significantly higher in psoriatic skin biopsy 
samples in comparison to the normal skin 
samples (Figure 4A-B). 
 
The upregulated expression of IL-8 and IL-33was 
further confirmed by western blot in one psoriatic 
and one normal skin samples and the protein 
expression of IL-8 and IL-33 correlated well with 




The results of immunohistochemistry revealed 
the presence of positively stained cells in 
psoriatic skin tissue indicating the expression of 
IL-8 and IL-33. However, no background staining 




Figure 3: Protein expression of CRHBP in normal and psoriasis skin biopsy samples determined by western blot 
analysis. Experiments were carried out in three biological replicates and presented as mean ± SD. The values 
were considered significant at *p < 0.01, **p < 0.001 and ***p < 0.0001 
 
 
Figure 4: Expression of (A) IL-8 and (B) IL-33 in normal and psoriasis skin biopsy samples determined by 
semiquatitative RT-PCR analysis. Experiments were carried out in three biological replicates and presented as 
mean ± SD. The values were considered significant at *p < 0.01, **p < 0.001 and ***p < 0.0001 
 




Figure 5: (A) Expression of IL-8 and IL-33 in normal and psoriasis skin biopsy samples determined by western 
blotting (B) quantification of IL-8 and IL-33 expression by densitometry. Experiments were carried out in three 
biological replicates and presented as mean ± SD. The values were considered significant at * p< 0.01, **p < 
0.001 and ***p < 0.0001 
 
 
Figure 6: Immunohistochemistry showing distribution of IL-8 and IL-33 (A) normal skin biopsy sample showing 
no expression (B) psoriasis skin biopsy sample showing expression of IL-8 and (C) psoriasis skin biopsy sample 




Psoriasis affects 3 % of the population around 
the world. In human, it is one of the prevalent T 
cell arbitrated inflammatory diseases. A highly 
elevated expression of cytokines has been 
reported in psoriasis which include but are not 
limited to IL-1, IL-6 and IL-12 [20].  
 
CRH is an important stress induced hormone 
that has been reported to trigger immune 
response indirectly [21]. In the current 
investigation, we examined the expression of 
CRH and correlated its expression with CRHBP, 
IL-8 and the newly included cytokine IL-33. CRH 
plays an important role in the hypothalamic 
pituitary adrenal (HPA) axis response to stress. 
At the same time, it also acts indirectly in an anti-
inflammatory response. In the current study, it 
was observed that expression of CRH was highly 
induced in psoriatic skin biopsy samples (Figure 
1). The results are in agreement with the studies 
carried out previously wherein the expression of 
CRH was reported to be highly induced of 
psoriatic samples.  
 
There are concrete evidences that the 
distribution and function of CRH is limited by the 
presence of CRHBP. Therefore, we evaluated 
the expression of CRHBP in both normal and 
psoriatic skin biopsy samples (Figure 2). It was 
observed that the mRNA expression of CRHBP 
was significantly low in case of psoriatic samples. 
These results suggested that the higher 
expression of CRH in psoriatic skin biopsy 
samples may be due to the unavailability of 
CRHBP. The expression of CRHBP was further 
confirmed by examining its expression at the 
protein level by western blotting. The results of 
western blots confirmed the mRNA expression 
determined by quantitative RT-PCR. 
Furthermore, it is believed that cytokines could 
be possible therapeutic targets for the treatment 
of psoriasis [22].  
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In the present study, we determined the 
expression of IL-8 and the new cytokine IL-33 in 
both the psoriatic and normal skin samples. The 
results suggested that mRNA expression of both 
the cytokines was highly elevated. This 
expression of IL-8 and IL-33 was further 
confirmed by western blotting. The results are in 
confirmation with previous studies wherein 
expression of several cytokines such as IL-1, IL-
2, IL-6, IL-12 and IL-19 was found to be 
upregulated in psoriatic tissues [23].  
 
While IL-8 was reported previously to be 
expressed in psoriasis [23], the present study 
represents one of the first studies that report the 
upregulation of IL-33 in psoriasis and IL-33 could 
therefore prove to be an important therapeutic 
target. Based on the results of immunostaining, 
we found that mononuclear leucocytes are 
possible sources of IL-33 in psoriatic lesions. 
Taken together, the results suggest that IL-33 
antagonists may prove to be important treatment 





The findings of the present study reveal that the 
expression of CRH is up-regulated in psoriatic 
skin biopsy samples. This may be attributed to 
the down-regulation of CRHBP. Furthermore, the 
expression of CRH in psoriatic tissues is 
associated with concomitant accumulation of IL-8 
and IL-33, indicating that CRH may trigger 
immune response in psoriasis by indirect 
stimulation of IL-8 and IL-33. Moreover, in view 
of the fact that IL-33 is highly expressed in 
psoriasis, IL-33 antagonists may prove an 
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